Related Experiment Video
Updated: Jun 3, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Novelties in the treatment for advanced renal-cell cancer]
1Szegedi Tudományegyetem, Általános Orvostudományi Kar Onkoterápiás Klinika Szeged Korányi fasor 12. 6720. dr.manna@freemail.hu
Abstract:
Therapeutic options in advanced renal-cell cancer have expanded through better understanding of molecular pathology and development of novel targeted therapeutics. Vascular endothelial growth factor, the key ligand of angiogenesis, has a major role in the progression of vascularized kidney tumors and this is the target molecule of modern medications. The three types of the mechanism of action of current therapies are: monoclonal antibodies blocking directly vascular endothelial growth factor ligand (bevacizumab), tyrosine-kinase inhibitors blocking vascular endothelial growth factor receptors (sorafenib, sunitinib, pazopanib) and inhibitors of the intracellular mTOR-kinase (temsirolimus, everolimus). Based on randomized studies, sunitinib, pazopanib or interferon-α-bevacizumab combination should be the first-line therapy in patients with good/moderate prognosis, while temsirolimus is recommended in those with poor prognosis. Following an ineffective cytokine therapy sorafenib or pazopanib are the second-line treatment. In case of tyrosine-kinase inhibitor inefficacy, current evidence favors everolimus. Patient outcome can further be improved by the involvement of more modern and effective target products.
Insights
Advanced renal cell cancer treatments now target vascular endothelial growth factor (VEGF) and its pathways. Targeted therapies like tyrosine kinase inhibitors and mTOR inhibitors offer improved outcomes for kidney cancer patients.
Area of Science:
- Oncology
- Molecular Pathology
- Pharmacology
Background:
- Advanced renal cell cancer (RCC) treatment landscape has evolved with a deeper understanding of molecular drivers.
- Vascular endothelial growth factor (VEGF) is crucial for angiogenesis in kidney tumors, making it a key therapeutic target.
Purpose of the Study:
- To review current targeted therapeutic strategies for advanced renal cell cancer.
- To outline the mechanisms of action and recommended sequencing of novel agents.
Main Methods:
- Analysis of randomized clinical trial data for targeted therapies in advanced RCC.
- Categorization of therapies based on molecular targets: VEGF ligand, VEGF receptors, and mTOR pathway.
Main Results:
- First-line therapy recommendations include sunitinib, pazopanib, or interferon-α-bevacizumab for good/moderate prognosis, and temsirolimus for poor prognosis.
- Second-line treatments after ineffective cytokine therapy are sorafenib or pazopanib.
- Everolimus is favored when tyrosine-kinase inhibitors are ineffective.
Conclusions:
- Current targeted therapies offer distinct mechanisms to combat advanced renal cell cancer.
- Strategic sequencing of these agents, guided by prognosis and prior treatment, is essential for optimizing patient outcomes.
- Continued development of novel targeted agents holds promise for further improving patient survival and quality of life.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...